Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$133.58 USD
+1.19 (0.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $133.46 -0.12 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$133.58 USD
+1.19 (0.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $133.46 -0.12 (-0.09%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
Zacks.com featured highlights include Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare
by Zacks Equity Research
Halozyme Therapeutics, Leidos Holdings, Atmos Energy and Addus HomeCare have been highlighted in this Screen of The Week article.
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.
Addus HomeCare (ADUS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Addus HomeCare (ADUS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 12.50% and 1.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ADUS vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare
by Zacks Equity Research
Quest Diagnostics, DaVita, Encompass Health and Addus HomeCare have been highlighted in this Industry Outlook article.
4 Stocks to Watch From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
Can Humana (HUM) Navigate Rising Expenses in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second-quarter results are expected to be impacted by declining Stand-Alone PDPs and total Specialty Medical membership levels.
Encompass Health (EHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Encompass Health (EHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Centene (CNC) Navigate Falling Memberships in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) second-quarter results are likely to reflect growing contributions from its Commercial business.
Addus HomeCare (ADUS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.
Top 5 Outpatient and Home Healthcare Stocks for Solid Returns
by Nalak Das
We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.
Compared to Estimates, Addus HomeCare (ADUS) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Addus HomeCare (ADUS) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 10% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Addus HomeCare (ADUS) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
ADUS vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Elevance Health (ELV), CD&R to Unveil Primary Care Offering
by Zacks Equity Research
Elevance Health (ELV) forms an alliance with CD&R to enhance primary care delivery by making collective use of the partners' assets and subsequently, reduce overall costs of care.
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
ADUS vs. USPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Acadia (ACHC) Buys CTCs to Boost Care Access in North Carolina
by Zacks Equity Research
Acadia Healthcare (ACHC) acquires three CTCs in the Raleigh, Greenville and Hillsborough regions of North Carolina, therefore increasing its CTC nationwide footprint and fetching improved revenues.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.